FDA has approved perioperative pembrolizumab for resectable head and neck squamous cell carcinoma, but do patients need ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the US Food and Drug Administration for the treatment of ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC ...

Pembrolizumab consistently improves overall and disease-free survival in clear cell renal cell carcinoma, showing sustained ...

Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...

The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors ...

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to advance at a resilient ...

MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...